Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Hellenic Society of Hematology
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05298683CT.gov A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor | — | Unknown | — | — | — |
NCT05147493CT.gov A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Kidney Failure
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Isatuximab (this asset) | Hellenic Society of Hematology | P2 | CCC · 53 |
| Normal Human Serum Albumin | Anna Cruceta | P4 | BBB |
| Midodrine | Anna Cruceta | P4 | BB |
| Dexasone | Augusta University | P3 | BB |
| Envarsus Product | University of Alberta | P4 | BB |
| Empagliflozin | University Hospital, Basel, Switzerland | P4 | BB |
| Lamivudine | Thomas Benfield | P4 | BB |
| Vildagliptin | Cairo University | P4 | BB |
| Metformin | Cairo University | P4 | BB |
+42 more in the Kidney Failure cohort
Other indications for Isatuximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Plasma Cell Myeloma | — | P4 | BB · 68 |
| Non-Hodgkin Lymphoma | — | P2 | B · 60 |
| Extranodal Nasal NK/T Cell Lymphoma | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Isatuximab in Kidney Failure. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/isatuximab-kidney-failure
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →